Lamivudine complexes with nucleic acids (green) in HBV polymerase, highlighting residues related to drug resistance.

SeqHepB is a web-based decision support tool to assist physicians to optimise and individualise the treatment schedule of patients with chronic hepatitis B. Evivar has the world's most complete collection of hepatitis B drug resistance mutations, which is stored in a searchable database linked to intelligent software through a web interface.

The use of currently available drugs for the treatment of CHB as well as the addition of more anti-viral drugs becoming available, will make the treatment landscape for CHB one where physicians are faced with an increasingly complex decision making process to optimise patient treatment.

The SeqHepB System is:

• Supported by extensive clinical case studies and clinical utility
• Detects new patterns of drug resistance as they occur
• Underpinned by a consortium of experts in the management of Hepatitis B
• Linked to phenotypic database of major HBV drug resistant mutants
• Built on the world's most complete collection of patented HBV drug resistance mutations

The SeqHepB System provides a physician with:

• Rapid analysis of the HBV genetic sequence from a patient undergoing antiviral treatment for CHB
• Identification and interpretation of HBV mutations
• Confirmation of resistance to specific therapies based on mutations present
• Dynamic database and analysis engine that provides the only complete, accurate and effective support tool for physicians

SeqHepB can also be used to map the mutational 'pathways' of resistance as well as the rapidly emerging clinical issues of cross-resistance (CR) and multi-drug resistance (MDR).

An HBV resistance profiling system must keep up with a virus that is continually changing. It is this unrelenting evolution during antiviral therapy that is at the centre of MDR. In terms of mutation, the HBV is not limited to point mutations but also has insertions and/or deletions causing mutational resistance.